Breast cancer supplement Nerlynx has become available in hospitals. According to related industries, Tyrosine kinase inhibitor Nerlynx (Neratinib), which inhibits Bixink's HER2 protein, passed the Drug Committee (DC) of medical institutions such as Seoul National University Hospital.

However, as it is still non-reimubrsement, it is expected to take time until Rx is activated. It was submitted to the HIRA's Cancer Disease Review Committee in February, but the standard was not set. Bixink plans to submit an application again in the second half of this year. HER2-positive early breast cancer has a 1.89 times higher risk of epilepsy than HER2-negative breast cancer. The high incidence of brain metastasis is